FGF1: Potential Drug Target and Biomarker (G2267)

Target Name: FGL1

NCBI ID: G2267

FGL1

FGF1: Potential Drug Target and Biomarker

FGF1 (Fibrinogen-like protein 1) is a protein that is expressed in various tissues throughout the body, including the liver, heart, kidneys, and pancreas. It is a member of the FGF family of proteins, which are characterized by the presence of a specific domain known as the FGF1 domain. This domain is responsible for the protein's ability to stimulate the production of fibrin, a protein that is involved in the formation of blood clots.

One of the unique features of FGF1 is its ability to interact with the protein Fc, which is a type of antibody that is found in the blood. This interaction between FGF1 and Fc allows FGF1 to bind to specific cell surfaces and stimulate the production of fibrin in those cells. This interaction between FGF1 and Fc is what makes it a potential drug target.

FGF1 has also been shown to be involved in the regulation of cell proliferation, which is important for the development and maintenance of tissues and organs. This involvement in cell proliferation makes FGF1 a potential biomarker for the diagnosis and treatment of various diseases.

One of the challenges in studying FGF1 is its complex structure. FGF1 is a member of the FGF family, which includes a variety of proteins with different lengths and shapes. This makes it difficult to study the protein's activity and determine how it interacts with other proteins.

In addition, the regulation of FGF1 has been shown to be involved in a wide range of physiological processes, including blood clot formation, tissue repair, and cell growth. This makes it difficult to study the protein's function and determine how it can be targeted to treat various diseases.

Despite these challenges, research into FGF1 is ongoing, and there is a growing interest in using it as a drug target or biomarker. One of the main goals of research into FGF1 is to understand its role in the development and treatment of various diseases, including cancer, heart disease, and diabetes.

In addition to its potential as a drug target or biomarker, FGF1 is also being studied for its potential use as a diagnostic tool. The regulation of FGF1 has been shown to be involved in the development and progression of a variety of diseases, including cancer. This makes it possible that changes in the level of FGF1 in certain cells could be an indication of the presence of these diseases.

Overall, FGF1 is a protein that is involved in a wide range of physiological processes, and its regulation is closely tied to the development and treatment of various diseases. As research into the protein continues, it is likely that new insights will emerge and new uses for it will be discovered.

Protein Name: Fibrinogen Like 1

Functions: Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a major ligand of LAG3 (PubMed:30580966). Responsible for LAG3 T-cell inhibitory function (PubMed:30580966). Binds LAG3 independently from MHC class II (MHC-II) (PubMed:30580966). Secreted by, and promotes growth of, hepatocytes (PubMed:11470158, PubMed:19880967)

The "FGL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets